Monitor for upcoming late-stage pipeline catalysts (RGX-202 for Duchenne, ABBV-RGX-314 for wet AMD/diabetic retinopathy) which are the primary value drivers. The board refresh is routine and does not change the near-term outlook.
Price Chart
Executive Summary
REGENXBIO appointed Greg Ciongoli as a Class II director and accepted the resignations of Jean Bennett and Jerry Karabelas, effective August 25, 2026. The board was reduced to nine members. This is a routine board refresh with no material financial impact, though Ciongoli's capital-markets background is notable as the company approaches late-stage pipeline catalysts.
Key Facts
- Greg Ciongoli elected as Class II director effective August 25, 2026.
- Ciongoli received an initial equity award with aggregate grant date fair value of $550,000 (75% stock option, 25% RSUs).
- Option exercise price: $8.91 per share.
- Jean Bennett, M.D., Ph.D. and A.N. Jerry Karabelas, Ph.D. resigned from the board effective August 25, 2026.
- Board size reduced to nine directors.
- Ciongoli will serve on the Audit Committee and Nominating and Corporate Governance Committee.
- Ciongoli is Founder and Managing Partner of Adiumentum Capital Management.
Financial Impact
Initial equity award of $550,000 to new director; annual retainers of $45,000 (board), $10,000 (Audit Committee), $5,000 (Nominating and Corporate Governance Committee).
Risk Factors
- No material financial or operational risks identified from this filing.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-365287 |
| Document: 0001193125-26-365287-index.html | 0001193125-26-365287 |
| Document: 0001193125-26-365287.txt | 0001193125-26-365287 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 27, 2026 5w ago | Insider Buy | $9.66 $7.47 | ▼ −22.67% | ▼ −22.93% | $7.43 (−23.08%) |
Aug 25, 2026 5w ago | 8-K | $9.38 $7.24 | ▼ −22.81% | ▼ −23.04% | $7.43 (−20.79%) |
Aug 6, 2026 8w ago | 8-K | $11.28 $9.20 | ▼ −18.44% | ▼ −19.04% | $7.43 (−34.13%) |
Aug 3, 2026 8w ago | Press Release | $9.96 $9.50 | ▼ −4.62% | ▼ −5.86% | $7.43 (−25.40%) |
Jul 20, 2026 10w ago | 8-K | $10.32 $11.33 | ▼ −9.79% | ▼ −5.67% | $7.43 (+28.00%) |
Jul 17, 2026 11w ago | Press Release | $9.89 $10.77 | ▼ −8.85% | ▼ −4.40% | $7.43 (+24.87%) |
Jun 29, 2026 13w ago | 8-K | $11.83 $9.73 | ▼ −17.75% | ▼ −17.47% | $7.43 (−37.19%) |
Jun 3, 2026 17w ago | 8-K | $6.69 $13.28 | ▲ +98.51% | ▲ +99.51% | $7.43 (+11.06%) |
May 14, 2026 20w ago | 8-K | $6.25 $6.66 | ▲ +6.65% | ▲ +7.50% | $7.43 (+18.98%) |
Mar 5, 2026 30w ago | 8-K | $8.72 $8.53 | ▼ −2.18% | ▲ +1.61% | $7.43 (−14.79%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access